On 17 January 2018 the Securitisation Regulation (EU) 2017-2402 (the SR) entered into force. The SR is available here. It applies from 1 January 2019.

The SR introduces an EU-wide set of uniform measures regulating the securitisation market. This marks a significant piece of the EUs Capital Markets Union (CMU) reform measures.

In an investment funds context, the SR impacts both AIFs and UCITS and significant points of note are-

  • This marks a shift whereby originators - sponsors - lenders will be directly obliged to meet the requirements of the SR rather than (as is currently the case under Directive 2011-61-EU (AIFMD) requiring the AIFM, as the investor, to determine that the originators - sponsors - lenders have complied.
  • While key differences remain between US and EU risk retention requirements for securitisations, this development more closely aligns the two regimes insofar as both regimes now seek to regulate the originators - sponsors - lenders.
  • Current due diligence, transparency and risk retention requirements in AIFMD, with respect to investment in securitisation positions will be repealed. Article 17 of AIFMD is replaced with a new provision stating that where AIFMs are exposed to securitisation positions which do not meet the requirements of the SR, the AIFM shall take corrective action.
  • The anomaly whereby UCITS were not subject to due diligence, transparency and risk retention requirements with respect to investment in securitisation positions has been rectified. Article 50a of the UCITS Directive is replaced with a new provision stating that where UCITS are exposed to securitisation positions which do not meet the requirements of the SR, the UCITS shall take corrective action.
  • The risk retention rules have been changed but the requirement that the originator - sponsor - lender retain an economic interest of not less than 5 in the securitisation has been retained.
  • There are transitional provisions for positions issued prior to the effective date of the SR (i.e. 1 January 2019). Our Structured Finance Group have extensive experience advising on securitisations and risk retention structures.

Further Information

Should you have any questions or would like to discuss the above, please contact your usual Maples and Calder contact.

CONTACTS

bioImage

Peter Stapleton

Partner

+353 1 619 2024

bioImage

Stephen Carty

Partner

+353 1 619 2023

bioImage

Eimear O'Dwyer

Partner

+353 1 619 2065

bioImage

Ian Conlon

Partner

+353 1 619 2714

bioImage

John Gallagher

Partner

+353 1 619 2073

bioImage

Deirdre McIlvenna

Partner

+353 1 619 2064

bioImage

Emma Conaty

Head of Global Registration Services

+353 1 619 2708

bioImage

Adam Donoghue

Partner

+44 20 7466 1711

bioImage

Pádraig Brosnan

Partner

+1 345 814 5441

*
*
*
*

Please note that your email may be received and read by other Maples and Calder lawyers in addition to your intended recipient.

*
*
*

Please note that your email may be received and read by other Maples Group employees in addition to your intended recipient.

Connect

Want to get in touch ?

Contact Us